CagriSema combines two compounds acting on different appetite pathways: Cagrilintide, a long-acting amylin analog (CALCR/RAMP receptor complex), and Semaglutide, a GLP-1 receptor agonist. Because the mechanisms are complementary rather than overlapping, the combination is studied for additive effects neither produces alone โ a textbook synergistic stack.
GLP-1 agonists engage a single satiety pathway. Adding an amylin analog recruits a second, independent one. This is the same logic behind pairing Cagrilintide with more potent agonists โ the pathways stack instead of competing, unlike two GLP-1s together (which just add side-effects).
In the REDEFINE 1 trial, CagriSema reported roughly 20% mean weight reduction โ between single-agonist Semaglutide (~15%, STEP) and dual/triple agonists like Tirzepatide (22.5%) and Retatrutide. These are published clinical figures for research context; the research chemicals sold by vendors are for laboratory use only.
Compare the two components and the pre-made blend across all 26 vendors, normalized to cost-per-milligram with codes applied:
Some vendors sell a ready-made Sema/Cagri blend โ Platinum Peptides carries one, 15% off with pepstracker15. Compare the blend vs. buying components separately.
Retatrutide vs Cagrilintide ยท Best peptides for fat loss
A combination of Cagrilintide (a long-acting amylin analog) and Semaglutide (a GLP-1 receptor agonist), engaging two different appetite pathways.
In published trials CagriSema reported ~20% weight reduction (REDEFINE 1), between single-agonist Semaglutide and dual/triple agonists like Tirzepatide (22.5%) and Retatrutide. It remains investigational.
It depends on vendor pricing and vial sizes โ compare both on PepsTracker by cost-per-milligram after discount codes.